New molecular imaging technique to support breast cancer treatment decisions
In a pioneering medical step that enhances the presence of precision medicine technologies in the Kingdom of Saudi Arabia, the I-ONE Molecular Imaging Center, a subsidiary of Wadi Jeddah Company, announced the commencement of accepting patients for advanced imaging tests (¹⁸F-FES PET/CT and PET/MRI). This step represents a qualitative leap in healthcare, as it provides advanced molecular imaging technology that supports precise clinical evaluation and guides treatment decisions for estrogen receptor-dependent breast cancer , opening new doors of hope and recovery for patients.
A historical development in tumor diagnosis and breast cancer treatment guidance
Historically, physicians have relied for many years on traditional examinations and tissue biopsies to determine the nature of tumors and the course of treatment for breast cancer. While these methods were effective, they faced challenges in some complex cases, such as difficulty accessing the tumor for biopsy or unclear laboratory results. With continuous scientific advancements in the global medical community, the urgent need arose for non-invasive techniques capable of providing a comprehensive and accurate picture. This is where positron emission tomography (PET) plays a crucial role, revolutionizing oncology by allowing visualization of cellular and molecular activity within the living body. This reduces the need for repeated surgical procedures and accelerates the accurate diagnosis process.
How does advanced molecular imaging technology work?
This new test gives physicians a broader and more comprehensive ability to assess functional estrogen receptors throughout the body. The significance of this technology lies in its addition of a vital functional dimension to medical imaging; it not only reveals the anatomical location of the disease but also contributes effectively to understanding estrogen receptor activity. This deeper understanding supports targeted hormonal therapy and precision medicine, particularly when biopsy is difficult to perform or traditional test results are unclear, thus ensuring that the patient is guided toward the most appropriate treatment plan for their specific condition.
Positive impacts on healthcare locally and regionally
The launch of this technology in Saudi Arabia carries significant strategic implications. Domestically, this achievement contributes to the goals of Saudi Vision 2030 related to improving quality of life and developing the healthcare sector by localizing cutting-edge medical technologies and reducing the need for patients to travel abroad for necessary care. Regionally, this development reinforces the Kingdom's position as a leading hub for medical innovation and precision medicine in the Middle East, potentially attracting patients from neighboring countries seeking accurate diagnoses. Internationally, the adoption of these technologies by centers like I-ONE aligns with modern global standards and opens avenues for research collaboration with international medical institutions to develop more effective treatment protocols.
Ongoing commitment to health innovation
The launch of this innovative service comes as part of the ongoing efforts of Wadi Jeddah and its subsidiaries to support healthcare innovation. Adopting advanced molecular imaging solutions enhances diagnostic quality and supports a comprehensive shift towards more precise and patient-centered healthcare, ensuring the delivery of medical services that meet the highest international standards and contribute to saving lives and improving patients' quality of life.
